Market Research Logo

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

Summary


The antibacterial drug market covers the drugs used in the prophylaxis and treatment of bacterial infections. With a growing global concern over antimicrobial resistance and its progressive growth, there is a pronounced need for innovation within this market. This report considers the key developments in this market, with particular focus on drugs indicated for use in pneumonia, methicillin-resistant staphylococcus aureus (MRSA), sepsis and tuberculosis.

Drugs for the prevention of bacterial infections are typically vaccines, which help to train the body’s immune system to fight off specific infections, and can therefore help to prevent infections of certain bacterial strains. However, several prophylactic monoclonal antibodies are also currently in development.

Drugs for the treatment of bacterial infections are slightly more varied. Most common are beta-lactam antibiotics, which include the very widely prescribed penicillin. However, bacteria have developed resistance to penicillin by producing beta-lactamase enzymes that break open the beta-lactam ring found in these antibiotics, rendering them ineffective. As a result modern beta-lactams are frequently combination drugs of a beta-lactam and a beta-lactamase inhibitor.

In addition to beta-lactams there are several other classes of drugs used to treat bacterial infections. These include fluoroquinolones, which inhibit DNA gyrase and/or topoisomerase IV; and protein synthesis inhibitors, which have applications within the treatment of bacteria that are resistant to beta-lactam antibiotics. However, bacterial resistance has also developed against these drugs, and as such there is a gap in the market for a new generation of drugs that are effective against drug-resistant bacteria.

The antibacterial market is currently dominated by vaccines, in particular those for the prevention of pneumococcal infections, diphtheria, tetanus and pertussis. However, recent years have seen key additions in the form of therapies for antibiotic-resistant bacteria, including strains with multi-drug resistance. The number of such products is expected to increase drastically between 2016 and 2022.

Scope

Antibiotic resistance has caused a surge in the development of antibiotics:

  • How big is the antibiotic pipeline?
  • How are companies attempting to overcome antibiotic resistance?
The antibacterial drug market is forecast to rise from around $27.1 billion in 2015 to $35.6 billion in 2022:
  • How much will the approval of new products and the patent expiries of existing ones contribute to this market growth?
  • Will vaccines continue to drive market revenue?
The pipeline contains a range of molecular targets:
  • Which molecular targets are most popular in the current pipeline?
  • How many late-stage products are active against drug-resistant bacteria?
  • What are the commercial prospects for the most promising late-stage pipeline products?
Big Pharma maintains a strong presence within the antibacterial drug market:
  • Which of the leading companies are expected to have the highest share of the market by 2022?
  • Which of the leading pharmaceutical companies are expected to bring new products to market during the forecast period?
  • Which companies rely heavily of revenues derived from antibacterial drugs?
Reasons to buy
  • Understand the current clinical and commercial landscape through a comprehensive analysis of innovation in the antibacterial drug market in the context of the overall pipeline and current market landscape. It also includes analysis of the deals landscape, including both licensing deals and co-development deals. Key indications covered in detail include pneumonia, MRSA, sepsis and tuberculosis.
  • Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
  • Analyze the antibacterial pipeline through a comprehensive review of the pipeline, segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at antibacterial drug clinical trials, to provide an insight into the risk associated with attempting to bring pipeline antibacterial drugs to market.
  • Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecast will provide an understanding of how epidemiology trends, new drug entries and new drug patent expirations will influence market value.
  • Identify the key pipeline products, with a particular focus on those due to be brought to market in the near future, as well as sales forecasts for these products.
  • Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from antibacterial products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
  • Assess the licensing and co-development deal landscape for antibacterial therapies.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease Cluster Introduction
2.2 Symptoms
2.2.1 Pneumonia
2.2.2 MRSA
2.2.3 Sepsis
2.2.4 Tuberculosis
2.3 Diagnosis
2.3.1 Pneumonia
2.3.2 MRSA
2.3.3 Sepsis
2.3.4 Tuberculosis
2.4 Etiology and Pathophysiology
2.4.1 Pneumonia
2.4.2 MRSA
2.4.3 Sepsis
2.4.4 Tuberculosis
2.5 Epidemiology
2.5.1 Pneumonia
2.5.2 MRSA
2.5.3 Sepsis
2.5.4 Tuberculosis
2.6 Comorbidities and Complications
2.6.1 Pneumonia
2.6.2 MRSA
2.6.3 Sepsis
2.6.4 Tuberculosis
2.7 Prognosis
2.7.1 Pneumonia
2.7.2 MRSA
2.7.3 Sepsis
2.7.4 Tuberculosis
2.8 Treatment
2.8.1 Beta-lactams
2.8.2 Protein Synthesis inhibitors
2.8.3 Vaccines
2.8.4 Other Classes of Antibacterial Therapy
3 Key Marketed Products
3.1 Overview
3.2 Cubicin (daptomycin) – Merck & Co
3.3 Augmentin – GlaxoSmithKline
3.4 Prevnar 13 – Pfizer
3.5 Infanrix – GlaxoSmithKline
3.6 Boostrix – GlaxoSmithKline
3.7 Zerbaxa – Merck and Co
3.8 Bexsero – GlaxoSmithKline
3.9 Zyvox – Pfizer
3.10 Conclusion
4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.3 Mechanisms of Action in Pipeline
4.4 Clinical Trial Landscape
4.4.1 Failure Rate by Stage of Development, Indication and Molecule Type
4.4.2 Clinical Trial Duration by Stage of Development, Indication, and Molecule Type
4.4.3 Clinical Trial Size by Stage of Development, Indication and Molecule Type
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication and Molecule Type
4.5 Conclusion
4.6 Assessment of Key Pipeline Products
4.6.1 Solithera – Cempra
4.6.2 Arikace – Insmed
4.6.3 Cadazolid – Actelion
4.6.4 Plazomicin (plazomicin sulfate) – Achaogen
4.6.5 V114 – Merck & Co.
4.6.6 Suvratoxumab (MEDI4893) – MedImmune
4.6.7 Pf-06290510 (SA4Ag vaccine) – Pfizer
4.6.8 PF-06425090 – Pfizer
4.6.9 Conclusion
5 Multi-Scenario Market Forecast to 2022
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Mechanism of Action
5.3.1 Immune Response
5.3.2 Bacterial Cell Wall Disruptor/Inhibitor
5.3.3 Protein Synthesis Inhibitors
5.3.4 DNA Inhibitors
5.3.5 Multiple Mechanisms of Action
6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.1.1 Pfizer – Will it Maintain its Position as Market Leader?
6.1.2 GlaxoSmithKline – Will Revenues for Key Products Continue to Grow Over Forecast Period?
6.1.3 Merck & Co – How Will Key Approvals and Patent Expiries Affect Revenue?
6.1.4 Allergan – Revenues to Rise Rapidly Following Market Entry
6.1.5 Cempra – Set to Enter the Market in 2017
6.1.6 Insmed – Set to Enter the Market in 2018
6.1.7 Otsuka – How Will the Approval of Deltyba Affect Otsuka’s Market Share?
6.1.8 Roche – Revenues to Continue to Decline Due to Lack of Pipeline Products
6.1.9 Bayer – Steady Decline as All Products Off-Patent
6.1.10 AstraZeneca – Set to Revitalize its Position within the Market
6.2 Company Landscape
6.3 Marketed and Pipeline Portfolio Analysis
7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Value and Year
7.1.2 Deals by Indication
7.1.3 Deals by Stage of Development and Value
7.1.4 Deals by Molecule Type, Mechanism of Action and Value
7.1.5 Licensing Deals Valued Above $100m
7.2 Co-development Deals
7.2.1 Deals by Region, Value and Year
7.2.2 Deals by Indication
7.2.3 Deals by Stage of Development and Value
7.2.4 Deals by Molecule Type and Value
7.2.5 Co-development Deals Valued Above $100m
8 Appendix
8.1 References
8.2 Table of all Pipeline Products
8.3 Table of Epidemiology Forecast
8.4 Abbreviations
8.5 Methodology
8.5.1 Coverage
8.5.2 Secondary Research
8.5.3 Market Size and Revenue Forecasts
8.5.4 Pipeline Analysis
8.5.5 Competitive Landscape
8.6 Contact Us
8.7 Disclaimer
1.1 List of Tables
Table 1: Antibacterial Drug Market, Global, Key Marketed Products and Approved Indications, 2016
Table 2: Antibacterial Drug Market, Global, Approved Indications for Cubicin, 2016
Table 3: Antibacterial Drug Market, Global, Approved Indications for Augmentin, 2016
Table 4: Antibacterial Drug Market, Global, Approved Indications for Prevnar 13, 2016
Table 5: Antibacterial Drug Market, Global, Approved Indications for Infanrix, 2016
Table 6: Antibacterial Drug Market, Global, Approved Indications for Boostrix, 2016
Table 7: Antibacterial Drug Market, Global, Approved Indications for Zerbaxa, 2016
Table 8: Antibacterial Drug Market, Global, Approved Indications for Bexsero, 2016
Table 9: Antibacterial Drug Market, Global, Approved Indications for Zyvox, 2016
Table 10: Antibacterial Drug Market, Global, Annual Revenue Forecast for Key Products ($m), 2015–2022
Table 11: Antibacterial Drug Market, Global, Usage of Generics Across Key Indications, 2015
Table 12: Antibacterial Drug Market, Global, Forecast Revenues by Company, 2015–2022
Table 13: Antibacterial Drug Market, Global, Licensing Deals Valued Above $100m, 2006–2016
Table 14: Antibacterial Drug Market, Global, Co-development Deals Above $100m, 2006–2016
Table 15: Antibacterial Drug Market, Global, Pipeline Products, Discovery, 2016
Table 16: Antibacterial Drug Market, Global, Pipeline Products, Preclinical, 2016
Table 17: Antibacterial Drug Market, Global, Pipeline Products, IND/CTA-filed, 2016
Table 18: Antibacterial Drug Market, Global, Pipeline Products, Phase I, 2016
Table 19: Antibacterial Drug Market, Global, Pipeline Products, Phase II, 2016
Table 20: Antibacterial Drug Market, Global, Pipeline Products, Phase III, 2016
Table 21: Antibacterial Drug Market, Global, Pipeline Products,Pre-registration, 2016
Table 22: Antibacterial Drug Market, Global, Pipeline Products, Unknown, 2016
Table 23: Antibacterial Drug Market, Prevalence Patterns for Pneumonia, 2015–2022
Table 24: Antibacterial Drug Market, Vaccinations Patterns for Pneumonia, 2015–2022
Table 25: Antibacterial Drug Market, Prevalence Patterns for Sepsis, 2015–2022
Table 26: Antibacterial Drug Market, Prevalence Patterns for Tuberculosis, 2015–2022
Table 27: Abbreviations
1.2 List of Figures
Figure 1: Antibacterial Drug Market, Global, Epidemiology Patterns for Pneumonia Incidence, 2015–2022
Figure 2: Antibacterial Drug Market, Global, Epidemiology Patterns for Pneumococcal Vaccinations, 2015–2022
Figure 3: Antibacterial Drug Market, Global, Epidemiology Patterns for Sepsis, 2015–2022
Figure 4: Antibacterial Drug Market, Global, Epidemiology Patterns for Tuberculosis, 2015–2022
Figure 5: Antibacterial Drug Market, Global, Annual Revenue for Cubicin ($m), 2006–2022
Figure 6: Antibacterial Drug Market, Global, Annual Revenue for Augmentin ($m), 2006–2022
Figure 7: Antibacterial Drug Market, Global, Annual Revenue for Prevnar 13 ($bn), 2009–2022
Figure 8: Antibacterial Drug Market, Global, Annual Revenue for Infanrix ($bn), 2006–2022
Figure 9: Antibacterial Drug Market, Global, Annual Revenue for Boostrix ($m), 2006–2022
Figure 10: Antibacterial Drug Market, Global, Annual Revenue for Zerbaxa ($m), 2016–2022
Figure 11: Antibacterial Drug Market, Global, Annual Revenue for Bexsero ($m), 2015–2022
Figure 12: Antibacterial Drug Market, Global, Annual Revenue for Zyvox ($bn), 2006–2022
Figure 13: Antibacterial Drug Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016
Figure 14: Antibacterial Drug Market, Global, Pipeline by Stage of Development and Molecule Type, 2016
Figure 15: Antibacterial Drug Market, Global, Pipeline, Key Indications by Stage of Development, 2016
Figure 16: Antibacterial Drug Market, Global, Pipeline, Key Indications Molecule Type, 2016
Figure 17: Antibacterial Drug Market, Global, Overall Pipeline by Mechanism of Action, 2016
Figure 18: Antibacterial Drug Market, Global, Pipeline by Mechanism of Action and Stage of Development, 2016
Figure 19: Antibacterial Drug Market, Global, Pipeline for Key Bacterial Indications by Mechanism of Action, 2016
Figure 20: Antibacterial Drug Market, Global, Clinical Trial Failure Rates by Stage of Development (%), 2006–2016
Figure 21: Antibacterial Drug Market, Global, Clinical Trial Failure Rates by Stage of Development and Indication (%), 2006–2016
Figure 22: Antibacterial Drug Market, Global, Clinical Trial Failure Rates by Stage of Development and Molecule Type (%), 2006–2016
Figure 23: Antibacterial Drug Market, Global, Clinical Trial Failure Rates by Stage of Development and Mechanism of Action (%), 2006–2016
Figure 24: Antibacterial Drug Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2016
Figure 25: Antibacterial Drug Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006–2016
Figure 26: Antibacterial Drug Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2016
Figure 27: Antibacterial Drug Market, Global, Clinical Trial Duration by Stage of Development and Mechanism of Action (months), 2006–2016
Figure 28: Antibacterial Drug Market, Global, Clinical Trial Size by Stage of Development (participants), 2006–2016
Figure 29: Antibacterial Drug Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006–2016
Figure 30: Antibacterial Drug Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006–2016
Figure 31: Antibacterial Drug Market, Global, Clinical Trial Size by Stage of Development and Mechanism of Action (participants), 2006–2016
Figure 32: Antibacterial Drug Market, Global, Aggregate Clinical Program Size by Stage of Development (participants), 2006–2016
Figure 33: Antibacterial Drug Market, Global, Aggregate Clinical Program Size by Stage of Development and Indication (participants), 2006–2016
Figure 34: Antibacterial Drug Market, Global, Aggregate Clinical Program Size by Stage of Development and Molecule Type (participants), 2006–2016
Figure 35: Antibacterial Drug Market, Global, Aggregate Clinical Program Size by Stage of Development and Mechansim of Action(participants), 2006–2016
Figure 36: Antibacterial Drug Market, Global, Revenue Forecast for Solithera ($m), 2017–2022
Figure 37: Antibacterial Drug Market, Global, Revenue Forecast for Arikace ($m), 2018–2022
Figure 38: Antibacterial Drug Market, Global, Revenue Forecast for Cadazolid ($m), 2017–2022
Figure 39: Antibacterial Drugs Market, Global, Revenue Forecast for Plazomicin ($m), 2018–2022
Figure 40: Antibacterial Drug Market, Global, Revenue Forecast for V114 ($m), 2019–2022
Figure 41: Antibacterial Drugs Market, Global, Revenue Forecast for MEDI4893 ($m), 2019–2022
Figure 42: Antibacterial Drugs Market, Global, Revenue Forecast for Pf-06290510 ($m), 2018–2022
Figure 43: Antibacterial Drugs Market, Global, Revenue Forecast for Pf-06425090 ($m), 2018–2022
Figure 44: Antibacterial Drug Market, Global, Market Size ($bn), 2015–2022
Figure 45: Antibacterial Drug Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2015–2022
Figure 46: Antibacterial Drug Market, Global, Annual Revenue Forecast for Drugs That Modify the Immune Response ($bn), 2015–2022
Figure 47: Antibacterial Drug Market, Global, Annual Revenue Forecast for Bacterial Cell Wall Disruptors/Inhibitors ($bn), 2015–2022
Figure 48: Antibacterial Drug Market, Global, Annual Revenue Forecast for Protein Synthesis Inhibitors ($bn), 2015–2022
Figure 49: Antibacterial Drug Market, Global, Annual Revenue Forecast for DNA Inhibitors ($bn), 2015–2022
Figure 50: Antibacterial Drug Market, Global, Annual Revenue Forecast for Drugs With Multiple Mechanisms of Action ($bn), 2015–2022
Figure 51: Antibacterial Drug Market, Global, Cluster by Growth and Market Share, 2015–2022
Figure 52: Antibacterial Drug Market, Global, Company Analysis Matrix, 2016
Figure 53: Antibacterial Drug Market, Global, Forecast Market Share by Company (%), 2015–2022
Figure 54: Antibacterial Drugs Market, Global, Companies by Compound Annual Growth Rate (%), 2015–2022
Figure 55: Antibacterial Drug Market, Global, Revenues by Product Type, 2015–2022
Figure 56: Antibacterial Drug Market, Global, Pfizer Annual Revenue Forecast, 2015–2022
Figure 57: Antibacterial Drug Market, Global, GlaxoSmithKline Annual Revenue Forecast, 2015–2022
Figure 58: Antibacterial Drug Market, Global, Merck & Co Annual Revenue Forecast, 2015–2022
Figure 59: Antibacterial Drug Market, Global, Allergan Annual Revenue Forecast, 2015–2022
Figure 60: Antibacterial Drug Market, Global, Cempra Annual Revenue Forecast, 2015–2022
Figure 61: Antibacterial Drug Market, Global, Insmed Annual Revenue Forecast, 2015–2022
Figure 62: Antibacterial Drug Market, Global, Otsuka Annual Revenue Forecast, 2015–2022
Figure 63: Antibacterial Drug Market, Global, Roche Annual Revenue Forecast, 2015–2022
Figure 64: Antibacterial Drug Market, Global, Bayer Annual Revenue Forecast, 2015–2022
Figure 65: Antibacterial Drug Market, Global, AstraZeneca Annual Revenue Forecast, 2015–2022
Figure 66: Antibacterial Drug Market, Global, Companies by Type, 2016
Figure 67: Antibacterial Drug Market, Global, Pipeline, Overall, High-Activity and Late-Stage Developers by Level of Specialization, 2016
Figure 68: Antibacterial Drug Market, Global, Proportion of Total Company Revenue Attributed to Antibacterial Disease, 2015–2022
Figure 69: Antibacterial Drugs Market, Global, Licensing Deals by Region, Value and Year, 2006–2016
Figure 70: Antibacterial Drug Market, Global, Licensing Deals by Indication, 2006–2016
Figure 71: Antibacterial Drug Market, Global, Licensing Deals by Stage of Development and Value, 2006–2016
Figure 72: Antibacterial Drug Market, Global, Licensing Deals by Molecule Type, Mechanism of Action and Aggregate Deal Value, 2006–2016
Figure 73: Antibacterial Drug Market, Global, Co-development Deals by Region, Value and Year, 2006–2016
Figure 74: Antibacterial Drug Market, Global, Co-development Deals by Indication and Value, 2006–2016
Figure 75: Antibacterial Drug Market, Global, Co-development Deals by Stage of Development and Value, 2006–2016
Figure 76: Antibacterial Drug Market, Global, Co-development Deals by Molecule Type, Mechanism of Action and Aggregate Deal Value, 2006–

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report